Cohen B A, Greenberger P A, Saini S
Department of Neurology, Northwestern University Medical School, Chicago, Illinois, USA.
Allergy Asthma Proc. 1998 Mar-Apr;19(2):85-8. doi: 10.2500/108854188778607200.
We report a case of a patient treated for relapsing multiple sclerosis (MS) with interferon beta-1b who developed a severe vasculitic-like skin reaction 9 months after initiation of interferon therapy. Prompt discontinuation of interferon beta-1b and institution of corticosteroid therapy was associated with complete resolution of the cutaneous lesions. Other potential causative agents were excluded by penicillin skin sensitivity testing or continuing use in the absence of adverse reactions. We conclude that a vasculitic-like cutaneous reaction to interferon beta-1b may occur long after institution of therapy in some MS patients. We review other case reports of severe cutaneous reactions associated with interferon beta-1b therapy in MS patients that suggest that susceptibility cofactors may be important elements in the occurrence of these reactions, and consider whether other medications commonly used in MS patients could have such a role.
我们报告了一例复发型多发性硬化症（MS）患者，该患者接受β-1b干扰素治疗，在开始干扰素治疗9个月后出现了严重的血管炎样皮肤反应。立即停用β-1b干扰素并开始使用皮质类固醇治疗后，皮肤病变完全消退。通过青霉素皮肤敏感性试验或在无不良反应的情况下继续使用，排除了其他潜在的致病因素。我们得出结论，在一些MS患者中，使用干扰素β-1b治疗后很长时间可能会出现血管炎样皮肤反应。我们回顾了其他与MS患者使用β-1b干扰素治疗相关的严重皮肤反应的病例报告，这些报告表明易感性辅助因素可能是这些反应发生的重要因素，并考虑MS患者常用的其他药物是否也可能起这样的作用。
